ECSP22072777A - [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 - Google Patents

[1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2

Info

Publication number
ECSP22072777A
ECSP22072777A ECSENADI202272777A ECDI202272777A ECSP22072777A EC SP22072777 A ECSP22072777 A EC SP22072777A EC SENADI202272777 A ECSENADI202272777 A EC SENADI202272777A EC DI202272777 A ECDI202272777 A EC DI202272777A EC SP22072777 A ECSP22072777 A EC SP22072777A
Authority
EC
Ecuador
Prior art keywords
diazino
pyrimidines
her2 inhibitors
her2
inhibitors
Prior art date
Application number
ECSENADI202272777A
Other languages
English (en)
Inventor
Julian Fuchs
Dirk Scharn
Matthias Treu
Birgit Wilding
Detrich Boese
Harald Engelhardt
Mark Petronczki
Ralph Neumueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22072777A publication Critical patent/ECSP22072777A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a [1,3]diazino[5,4-d]pirimidinas novedosas y derivados de la Fórmula (I) en donde los grupos R1, R2, R3 y R4 tienen los significados que se proporcionan en las reivindicaciones y la memoria descriptiva, su uso como inhibidores de HER2 y sus mutantes, composiciones farmacéuticas que contienen tales compuestos y su uso como medicamentos, especialmente como agentes para el tratamiento y/o la prevención de enfermedades oncológicas.
ECSENADI202272777A 2020-04-24 2022-09-21 [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 ECSP22072777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20171221 2020-04-24
PCT/EP2021/059015 WO2021213800A1 (en) 2020-04-24 2021-04-07 [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS

Publications (1)

Publication Number Publication Date
ECSP22072777A true ECSP22072777A (es) 2022-10-31

Family

ID=70470818

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202272777A ECSP22072777A (es) 2020-04-24 2022-09-21 [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2

Country Status (19)

Country Link
US (2) US11608343B2 (es)
EP (1) EP4139309A1 (es)
JP (2) JP7260723B2 (es)
KR (1) KR20230005263A (es)
CN (1) CN115485277B (es)
AR (1) AR121779A1 (es)
AU (1) AU2021260721A1 (es)
BR (1) BR112022021514A2 (es)
CA (1) CA3173602A1 (es)
CL (1) CL2022002579A1 (es)
CO (1) CO2022015054A2 (es)
CR (1) CR20220537A (es)
DO (1) DOP2022000189A (es)
EC (1) ECSP22072777A (es)
IL (1) IL297490A (es)
MX (1) MX2022013223A (es)
PE (1) PE20230827A1 (es)
TW (1) TW202206432A (es)
WO (1) WO2021213800A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
WO2022266458A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-heterocycloalkyl-quinazoline derivatives and uses thereof
WO2023154124A1 (en) * 2022-02-09 2023-08-17 Enliven Therapeutics, Inc. Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
KR20230143959A (ko) * 2022-04-05 2023-10-13 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2024027695A1 (zh) * 2022-08-04 2024-02-08 微境生物医药科技(上海)有限公司 作为her2抑制剂的化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
BR0214499A (pt) 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
BRPI0416190A (pt) 2003-11-06 2007-01-23 Pfizer Prod Inc combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
EP1971601B1 (en) 2005-11-15 2009-10-21 Array Biopharma Inc. N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
DK3157916T3 (en) 2014-06-19 2019-03-18 Ariad Pharma Inc HETEROARYL COMPOUNDS FOR CHINESE INHIBITION
JP6863901B2 (ja) 2015-05-13 2021-04-28 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
JP2021501123A (ja) 2017-08-31 2021-01-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒおよび／またはｈｅｒ２の阻害剤ならびに使用方法
US11578074B2 (en) 2017-09-01 2023-02-14 Shanghai Pharmaceuticals Holding Cd., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
JP2023512174A (ja) 2020-02-03 2023-03-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
US20230131720A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors

Also Published As

Publication number Publication date
CL2022002579A1 (es) 2023-05-19
CR20220537A (es) 2022-12-06
KR20230005263A (ko) 2023-01-09
AU2021260721A1 (en) 2022-09-15
CO2022015054A2 (es) 2023-02-16
DOP2022000189A (es) 2022-09-30
EP4139309A1 (en) 2023-03-01
CN115485277A (zh) 2022-12-16
US20210332054A1 (en) 2021-10-28
BR112022021514A2 (pt) 2023-01-24
AR121779A1 (es) 2022-07-06
PE20230827A1 (es) 2023-05-19
IL297490A (en) 2022-12-01
TW202206432A (zh) 2022-02-16
CA3173602A1 (en) 2021-10-28
JP7260723B2 (ja) 2023-04-18
CN115485277B (zh) 2024-05-14
WO2021213800A1 (en) 2021-10-28
US20230374021A1 (en) 2023-11-23
US11608343B2 (en) 2023-03-21
JP2023085489A (ja) 2023-06-20
JP2023512343A (ja) 2023-03-24
MX2022013223A (es) 2022-11-14

Similar Documents

Publication Publication Date Title
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CL2021000191A1 (es) Inhibidores de inflamasoma nlrp3
DOP2022000266A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
CL2019003239A1 (es) Amidas de piridona deuteradas y profármacos de los mismos como moduladores de canales de sodio.
BR112018007155A2 (pt) novos compostos de espiro[3h-indol-3,2?-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
UY29384A1 (es) Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes.
CL2012000059A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
DOP2011000218A (es) Derivados de sulfonamida
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY28695A1 (es) Derivados de difenilazetidona
UY30617A1 (es) Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones
UY29009A1 (es) Nuevos derivados de pirimidina, sales y solvatos farmaccuticamente aceptables de los mismos, composiciones, procedimientos para su preparacinn y uso.
HN2008001666A (es) Derivados acidos de cicloalquilamino
ECSP055958A (es) 4-aminopirimidina-5-ona
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CL2022003646A1 (es) Derivados de amidopirimidona
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados